Affordable Access

Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.

Authors
Type
Published Article
Journal
Diabetes Care
0149-5992
Publisher
American Diabetes Association
Publication Date
Volume
23
Issue
7
Pages
979–983
Identifiers
PMID: 10895850
Source
Medline
License
Unknown

Abstract

Combination therapy with repaglinide and troglitazone leads to better glycemic control than monotherapy with either agent alone. Repaglinide monotherapy was more effective in lowering HbA1c levels than troglitazone monotherapy Repaglinide/troglitazone combination therapy was effective and did not show unexpected adverse events.

Statistics

Seen <100 times